Clinical trial NCT00706615: Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer
Official title: A Single Arm Open-Label Phase I Study of An Injectable Replication-Incompetent Adenoviral Vector Vaccine Used to Produce An Immune Response to MUC-1 Positive Epithelial Cancer Cells in Metastatic Breast Cancer
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Breast Cancer
Keywords: stage IV breast cancer
recurrent breast cancer
Lead sponsor: Jonsson Comprehensive Cancer Center
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2008-06-27
Enrollment: 0
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Primary purpose: TREATMENT

Brief summary: RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating women with previously treated metastatic breast cancer.

Detailed description: OBJECTIVES:

Primary

* Characterize the safety profile of Ad-sig-hMUC-1/ecdCD40L vaccine in women with metastatic breast cancer.
* Identify a tolerable, immunologically active dose level of this vaccine in these patients.

Secondary

* Evaluate the immune function in these patients before and after treatment with this vaccine.

OUTLINE: Patients receive MUC-1 vector vaccine subcutaneously on day 0.

After completion of study treatment, patients are followed monthly for 9 months.

Eligibility criteria: Inclusion Criteria:

* Women over the age of 18 with metastatic or non-measureable adenocarcinoma of the breast with marrow involvement.
* Elevated serum MUC-1 levels, as measured by CA 15-3 or CA 27-29
* Stable disease (defined as fluctuation of \<50U in CA15-3 or CA27-29 value) for at least 3 months while either on no breast-cancer therapy or while on current therapy (Tamoxifen, fulvestrant, exemestane, letrozole, anastrozole, bisphosphonates or trastuzumab chemotherapy is not allowed)
* ability to understand the risks, benefits, and procedures and provide written informed consent.
* less than 28 days prior to enrollment since last surgery and/or radiation therapy.
* performance status \<=2 on the ECOG performance scale and life expectancy of greater than 12 months
* NYHA cardiac function Class I or Class II and normal baseline ECG. If ECG is abnormal, patient must have an echocardiogram showing a left ventricular ejection fraction greater than the lower limits of normal.
* patients who do not have radiographically assessable locally recurrent or metastatic disease are eligible if they 1) had radiographic or biopsy proven locally recurrent or metastatic breast cancer in the past and 2) currently (at study entry) have an elevated serum MUC-1 level (as measured by CA 15-3 or CA 27-29).
* Acceptable pulmonary function. if questionable, a pulmonary function test will be performed.
* negative serology for hepatitis B, C and HIV.
* red cell mean corpuscular volume \>- 80 cu. mm, hemoglobin \>- 8g/dl, platelet count \>- 100,000/dl: AST, ALT, LDH \<-2 times the Upper limit of normal
* Serum creatinine \< 1.6 mg/dL
* for women with child bearing potential, Negative urine pregnancy test within 7 days of registration and willingness to use an approved contraceptive method while participating in this trial.

Exclusion Criteria:

* history of bronchospasm or asthma requiring inhaled or oral steroid treatment
* Normal MUC-1 (CA 15-3 or CA 27-29)
* treatment with steroid or other immunosuppressive medication (for any condition ) within 30 days of trial registration.
* history of any autoimmune disease (e.g., lupus, rheumatoid arthritis, or psoriasis)
* uncontrolled diabetes mellitus
* unable or unwilling to undergo repeated clinical evaluations and other diagnostic procedures or unable to sign an informed consent.
* history of other malignancies, except squamous cell or basal cell carcinoma of the skin or cervical carcinoma in situ.
* Concurrent systemic chemotherapy (tamoxifen, aromatase inhibitors, fulvestrant, trastuzumab and biophosphonates are allowed if started more than 3 months prior to trial registration with evidence of stable disease as defined above. Chemotherapy must have stopped 3 months prior to enrolling in this trial).
* history of ornithine transcarbamylase deficiency
* any acute or chronic viral, bacterial, or fungal infection requiring specific therapy, unless acute therapy was completed within the past 14 days
* No underlying conditions that would contraindicate therapy with study treatment ( or allergies to reagents used in this study)
* history of organ transplant or allogeneic bone marrow transplant
* life threatening or organ-threatening disease expected to require conventional therapy within 4 months.
* pregnant or nursing females.

Primary outcomes:
measure: Characterize the safety profile of the Ad-sig-hMUC-1/ecdCD40L vector vaccine
measure: Identification of a tolerable, immunologically active dose level
Secondary outcomes:
measure: Assess efficacy based on serum MUC-1 level
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Jonsson Comprehensive Cancer Center at UCLA
state: California
Study officials:
affiliation: Jonsson Comprehensive Cancer Center
name: Sara Hurvitz, MD
role: PRINCIPAL_INVESTIGATOR
References: